GSK3B and early-onset autosomal dominant Alzheimer disease: GSK3β dysregulation, particularly hyperactivation, has been associated with various pathological conditions, including diabetes mellitus, inflammation, pulmonary hypertension and Alzheimer’s disease [9, 11–13].